Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID

Hemopurifier®癌症试验中三名患者接受治疗；获得印度监管批准；运营费用降低；研发进展支持扩展适应症，包括长期COVID。

Conference Call to be Held Today at

电话会议将于今天举行

4:30 p.m. ET

下午4点30分（东部时间）

SAN DIEGO

圣地亚哥

,

，

June 26, 2025

2025年6月26日

/PRNewswire/ --

/PRNewswire/ --

Aethlon Medical, Inc.

Aethlon医疗公司

(the Company or Aethlon) (Nasdaq:

（公司或Aethlon）（纳斯达克：

AEMD

AEMD

), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended

），一家专注于开发治疗癌症和危及生命的传染病产品的医疗治疗公司，今天公布了其财政年度第四季度的财务结果，截至

March 31, 2025

2025年3月31日

, and provided an update on recent developments.

，并提供了最近的发展更新。

Key Fiscal 2025 Highlights

关键财政2025亮点

First three patients treated in Hemopurifier® cancer trial at Australian sites

在澳大利亚站点进行的Hemopurifier®癌症试验中，前三名患者已接受治疗。

Indian regulatory approval received to initiate a similar oncology study

印度监管机构批准启动类似的肿瘤学研究

Study protocol expanded to reflect evolving immunotherapy standard of care

研究方案扩展以反映不断发展的免疫治疗标准护理

Preclinical data demonstrate 98.5% removal of platelet-derived EVs in simulated Hemopurifier® treatment

临床前数据表明，在模拟的Hemopurifier®治疗中，血小板衍生的EVs去除率达到98.5%。

Collaboration with UCSF to investigate Long COVID with findings to be presented at the Keystone Symposium

与UCSF合作研究长期COVID，研究成果将在基斯通研讨会上展示。

Operating expenses reduced significantly through streamlined operations

通过简化运营，经营费用显著减少。

Clinical Progress in Cancer Trial

癌症试验中的临床进展

Aethlon completed Hemopurifier treatments in the first three participants enrolled in its safety, feasibility, and dose-finding study of patients with solid tumors unresponsive to anti-PD-1 agents. Participant #1 was treated at Royal Adelaide Hospital in

Aethlon已完成其针对对anti-PD-1药物无反应的实体瘤患者的安全性、可行性和剂量探索研究中，前三位参与者的Hemopurifier治疗。参与者#1在皇家阿德莱德医院接受治疗。

January 2025

2025年1月

, while Participants #2 and #3 received treatment at Royal North Shore Hospital in

，而参与者#2和#3在皇家北岸医院接受治疗。

Sydney

悉尼

in

在

June 2025

2025年6月

. All participants completed a single 4-hour Hemopurifier treatment without device deficiencies or immediate complications and have now completed the pre-specified 7-day safety follow-up.

所有参与者均完成了一次4小时的Hemopurifier治疗，设备无故障，也未出现即时并发症，并且现已完成了预先规定的7天安全性随访。

This milestone triggers the first meeting of an independent Data Safety Monitoring Board (DSMB), to review safety data and recommend advancement to the second treatment cohort.  In the next cohort, participants will receive two Hemopurifier treatments during a one-week period.

这一里程碑触发了独立数据安全监测委员会 (DSMB) 的首次会议，以审查安全性数据并推荐进入第二个治疗队列。在下一个队列中，参与者将在一周内接受两次 Hemopurifier 治疗。

Preliminary data from the first cohort, including effects on extracellular vesicle (EV) removal and anti-tumor T-cell activity, are expected in approximately three months.

预计大约三个月后会获得包括对细胞外囊泡（EV）清除和抗肿瘤T细胞活性影响在内的第一组初步数据。

In parallel, the trial protocol was amended to broaden eligibility to include patients receiving combination therapies with Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®), in line with current treatment practices.

同时，试验方案进行了修订，以扩大符合条件的患者范围，纳入接受帕博利珠单抗（Keytruda®）或纳武利尤单抗（Opdivo®）联合治疗的患者，这与当前的治疗实践相符。

Currently, only about 30% of patients receiving pembrolizumab or nivolumab experience lasting clinical responses. EVs released by tumors have been implicated in cancer progression and resistance to anti-PD-1 therapies. The Hemopurifier® is designed to bind and remove these EVs from the bloodstream, potentially improving the therapeutic response rates to anti-PD-1 antibodies.

目前，只有大约30%的患者在接受派姆单抗或尼伏鲁单抗治疗后产生持久的临床反应。肿瘤释放的胞外囊泡（EVs）被认为与癌症进展及对PD-1抗体疗法的耐药性有关。Hemopurifier®旨在结合并去除血液中的这些胞外囊泡，可能提高对PD-1抗体治疗的疗效反应率。

In preclinical studies, the Hemopurifier has been shown to reduce the number of EVs in cancer patient plasma samples..

在临床前研究中，Hemopurifier 已被证明能够减少癌症患者血浆样本中的 EV 数量。

As a reminder, the primary endpoint for the approximate 9 to 18-patient study is safety.  The trials will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals.  Patients who do not respond to the PD-1 antibody therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period..

作为提醒，这项大约9到18名患者的研究的主要终点是安全性。试验将监测任何不良事件以及在不同治疗间隔接受Hemopurifier治疗的实体瘤（病情稳定或进展）患者的实验室检测结果中具有临床意义的变化。对PD-1抗体疗法无反应的患者将有资格进入Hemopurifier研究阶段，其中序贯队列将在一周内接受1次、2次或3次Hemopurifier治疗。

In addition to safety, the study includes exploratory analyses evaluating how many Hemopurifier® treatments are needed to decrease the concentration of EVs, and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells.  These findings are intended to guide the design of future safety and efficacy trials, including a potential Premarket Approval (PMA) study required by the FDA and other global regulatory agencies..

除了安全性之外，该研究还包括探索性分析，评估需要多少次Hemopurifier®治疗来降低EVs的浓度，以及这些EV浓度的变化是否能增强身体自身攻击肿瘤细胞的自然能力。这些发现旨在指导未来安全性和有效性试验的设计，包括FDA和其他全球监管机构要求的潜在上市前批准（PMA）研究。

Regulatory Approval India

印度监管批准

On

在

June 19, 2025

2025年6月19日

, the Company received formal approval from

，公司收到了来自

India's

印度的

Central Drugs Standard Control Organization (CDSCO) to initiate a similar trial at Medanta Medicity Hospital.  The approval followed a meeting with the Subject Expert Committee and prior Ethics Committee clearance.  The trial will begin following a Site Initiation Visit (SIV) conducted by Aethlon's .

中央药品标准控制组织（CDSCO）将在Medanta Medicity医院启动类似的试验。该批准是在与主题专家委员会开会并事先获得伦理委员会批准后作出的。试验将在Aethlon进行现场启动访问（SIV）后开始。

India

印度

-based CRO, Qualtran.

基于CRO的Qualtran。

Preclinical Study Supports Broader Applications

临床前研究支持更广泛的应用

On

在

May 12, 2025

2025年5月12日

, the results from Aethlon's preclinical ex vivo study were published in bioRxiv, and the manuscript has been submitted to a peer-reviewed journal for publication.  Those results showed that the Hemopurifier, using proprietary Galanthus nivalis agglutin (GNA) affinity resin, removed 98.5% of platelet -derived extracellular vesicles (PD-EVs) from human plasma during a timepoint equivalent to a 4-hour HP treatment.  Excessive levels of PD-EVs have been implicated in a myriad of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, acute and Long COVID.

Aethlon 的临床前离体研究结果已在 bioRxiv 上发表，并且该手稿已提交给同行评审期刊进行发表。结果显示，使用专有的雪花莲凝集素（GNA）亲和树脂的 Hemopurifier 在相当于 4 小时 HP 治疗的时间点内，去除了人血浆中 98.5% 的血小板衍生细胞外囊泡（PD-EVs）。PD-EVs 的过量水平与多种疾病有关，包括癌症、狼疮、系统性硬化症、多发性硬化症、阿尔茨海默病、败血症、急性新冠和长期新冠。

The results of this study support the ongoing oncology trial in .

这项研究的结果支持正在进行的肿瘤学试验。

Australia

澳大利亚

and suggest potential applications of the Hemopurifier in other EV-associated diseases.

并建议Hemopurifier在其他EV相关疾病中的潜在应用。

The manuscript describing this study has been submitted to a peer-reviewed journal for publication.

描述本研究的手稿已提交给同行评审期刊以待发表。

Scientific Collaboration in Long COVID Research

长新冠研究中的科学合作

Aethlon's collaborative research with the UCSF Long COVID Clinic was accepted for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes (

Aethlon与加州大学旧金山分校（UCSF）长期COVID诊所的合作研究被接受为Keystone研讨会关于长期COVID和其他急性感染后综合症的海报展示。

August 10-13

8月10日至13日

, 2025).   The study analyzed blood samples from participants with Long COVID as well as controls that had recovered from COVID-19 infection to evaluate the binding of larger and smaller extracellular vesicles to the Hemopurifier's lectin affinity resin, respectively.  These findings build on prior clinical evidence and support further investigation of the Hemopurifier in Long COVID, an unmet medical need affecting approximately 44 and 48 million people in .

，2025）。该研究分析了长新冠患者以及已从新冠感染中康复的对照组参与者的血液样本，以分别评估较大和较小的细胞外囊泡与Hemopurifier凝集素亲和树脂的结合情况。这些发现建立在先前的临床证据基础上，并支持进一步研究Hemopurifier在长新冠中的应用，这一未满足的医疗需求影响着约4400万至4800万人。

the United States

美国

alone, with an estimated economic burden of

独自承担，估计经济负担为

2 billion dollars

20亿美元

in those with symptoms lasting a year.

症状持续一年的人。

Operational Achievements

运营成果

In fiscal 2025, Aethlon streamlined operations and significantly reduced its operating expenses, positioning the company for sustained focus on its clinical and regulatory goals.

在2025财年，Aethlon简化了运营并大幅削减了运营费用，使公司能够持续专注于其临床和监管目标。

Financial Results for the Fiscal Fourth Quarter Ended

截至财政第四季度末的财务结果

March 31, 2025

2025年3月31日

As of

截至

March 31, 2025

2025年3月31日

, Aethlon had a cash balance of approximately

，Aethlon 的现金余额约为

$5.5 million

550万美元

.

。

Consolidated operating expenses for the fiscal year ended

截至财政年度末的合并营业费用

March 31, 2025

2025年3月31日

, were approximately

，大约是

$9.3

9.3美元

million, representing a decrease of

百万，表示减少了

$3.3 million

330万美元

or approximately 26%, compared to

或大约 26%，相比

$12.6 million

1260万美元

for the fiscal year ended

截至财政年度结束

March 31, 2024

2024年3月31日

. This reduction was primarily driven by lower payroll and related expenses, professional fees, and general and administrative costs.

. 这一减少主要是由于工资和相关费用、专业费用以及一般行政成本的降低所推动的。

Payroll and related expenses declined by an approximate

工资和相关费用下降了大约

$1.3 million

130万美元

, reflecting an approximate

，反映了大约

$900,000

90万美元

reduction in salaries and related expenses and an approximate

减少工资和相关费用以及大约

$800,000

80万美元

decrease in stock-based compensation. These reductions were primarily attributable to the termination of three executives—one in the fiscal year 2024, one in July and October 2024—and a workforce reduction of non-executive staff in

股票薪酬减少。这些减少主要归因于三名高管的离职——一名在2024财年，一名在2024年7月，一名在2024年10月——以及非高管员工的裁员。

August 2024

2024年8月

. The decrease in stock-based compensation was primarily due to the absence of accelerated vesting charges recognized in the prior year related to the termination of our former Chief Executive Officer, as well as reduced expenses following the departure of executives and staff. These decreases were partially offset by an increase of approximately .

股票薪酬的减少主要是由于前一年与前首席执行官解雇相关的加速归属费用未被计入，以及高管和员工离职后的费用减少。这些减少部分被大约 的增加所抵消。

$400,000

400,000美元

in severance expenses associated with the termination of two former executives.

与两名前高管的解雇相关的遣散费用。

Professional fees also declined by approximately

专业费用也下降了大约

$1.3 million

130万美元

.  This decrease includes

。这一减少包括

$600,000

60万美元

in legal costs savings resulting from a transition to a new legal firm, and an approximate

由于过渡到新的律师事务所而产生的法律费用节省，以及大约

$500,000

50万美元

related to the termination of services with a contract manufacturing organization and the completion of a project that involved using an outside lab to process samples.  Consulting fees related to scientific projects and regulatory projects declined by approximately

与终止同一家合同制造组织的服务以及完成一个涉及使用外部实验室处理样品的项目有关。与科学项目和监管项目相关的咨询费下降了大约

$300,000

30万美元

. These reductions were partially offset by an approximate

。这些减少部分被大约

$85,000

85,000美元

increase in accounting fees associated with obtaining audit firm consents for various securities filings.

与获取审计公司对各种证券文件的同意相关的会计费用增加。

General and administrative expenses decreased by approximately

一般和行政开支减少了大约

$660,000

66万美元

. The reduction was driven primarily by a

. 减少主要是由

$534,000

534,000美元

reduction in costs related to fewer raw material purchases, no cleanroom certification expenses, and reduced reliance on outside services for maintenance of the manufacturing facility. Laboratory supplies and testing costs also declined by

与减少原材料采购、无洁净室认证费用以及降低对制造设施维护的外部服务依赖相关的成本降低。实验室用品和测试成本也下降了。

$337,000

337,000美元

following the completion of oncology and transplant-related projects. Insurance expenses decreased by

在完成肿瘤学和移植相关项目后，保险费用减少了

$141,000

141,000美元

, reflecting lower medical and workers' compensation premiums due to reduced headcount, as well as an overall decrease in business insurance costs. Additional reductions included

，反映了由于员工人数减少而导致的医疗和工伤赔偿保费降低，以及商业保险成本的总体下降。额外的减少包括

$44,000

44,000美元

in travel and entertainment expenses,

在旅行和娱乐费用方面，

$24,000

24,000美元

decrease in office supplies, and

办公用品减少，以及

$19,000

19,000美元

in depreciation expense related to the disposal of certain equipment. These decreases were partially offset by a

与处置某些设备相关的折旧费用。这些减少部分被

$467,000

467,000美元

increase in clinical trial expenses associated with our ongoing oncology study in

与我们正在进行的肿瘤学研究相关的临床试验费用增加

Australia

澳大利亚

.

。

As a result of the above factors, our operating loss decreased to

由于上述因素，我们的营业亏损减少到

$9.3 million

930万美元

for the fiscal year ended

截至财政年度结束

March 31, 2025

2025年3月31日

, from

，来自

$12.6 million

1260万美元

for the fiscal year ended

截至财政年度结束

March 31, 2024

2024年3月31日

.

。

Other Income (Expense)

其他收入（支出）

Other expenses for the year ended

截至年度末的其他费用

March 31, 2025

2025年3月31日

, included a non-cash charge of approximately

，包括大约的非现金费用

$4.6 million

460万美元

related to a warrant inducement offer. In

与认股权证诱导要约相关。在

March 2025

2025年3月

, we offered certain warrant holders the opportunity to exercise existing warrants at a temporarily reduced exercise price in exchange for the issuance of new warrants. The inducement expense recognized represents the combined fair value of the new warrants issued and the incremental fair value resulting from the modification of the exercise price of the existing warrants.

我们为某些认股权证持有人提供了以临时降低的行权价格行使现有认股权证的机会，以换取发行新的认股权证。所确认的诱导费用代表了新发行认股权证的公允价值与现有认股权证行权价格修改所产生的增量公允价值的总和。

This transaction did not impact cash flows from operating activities..

此交易未影响经营活动产生的现金流量。

During the fiscal year ended

在财政年度结束期间

March 31, 2025

2025年3月31日

, we recognized approximately

，我们大约确认了

$324,450

324,450美元

in other income related to the Employee Retention Tax Credit (ERTC) under the CARES Act and subsequent legislation. We recorded the ERTC as other income in the periods in which the payments were received. In addition, we recognized

与《关怀法案》及后续立法下的员工保留税收抵免（ERTC）相关的其他收入。我们在收到款项的期间将ERTC记录为其他收入。此外，我们确认了

$36,339

36,339美元

in interest income related to the ERTC during fiscal 2025. As of

与2025财年ERTC相关的利息收入。截至

March 31, 2025

2025年3月31日

, the remaining expected credit was recorded as a receivable within other current assets on our consolidated balance sheet. No amounts were recorded in the prior fiscal year.

，剩余的预期信用被记录在我们合并资产负债表的其他流动资产中的应收款项。上一财年未记录任何金额。

The consolidated balance sheets for

合并资产负债表

March 31, 2025

2025年3月31日

and

和

March 31, 2024

2024年3月31日

, and the consolidated statements of operations for the fiscal years ended

，以及截至财政年度末的综合运营报表

March 31, 2025

2025年3月31日

and 2024 follow at the end of this release.

2024年紧随此版本之后。

Conference Call

电话会议

Management will host a conference call today,

管理层将于今天主持电话会议，

Thursday, June 26, 2025

2025年6月26日，星期四

, at

，位于

4:30 p.m. ET

下午4点30分（东部时间）

to review the company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

审查公司的财务结果和最近的公司发展。管理层的正式讲话之后，将有一个问答环节。

Interested parties can register for the conference call by navigating to

感兴趣的各方可以通过导航到以下地址注册参加电话会议：

https://dpregister.com/sreg/10200578/ff60012c0c

https://dpregister.com/sreg/10200578/ff60012c0c

. Please note that registered participants will receive their dial-in number upon registration.

请注意，注册参与者将在注册时收到他们的拨入号码。

Interested parties without internet access or unable to pre-register may dial in by calling:

没有网络访问权限或无法预先注册的相关方可以通过拨打以下电话号码加入：

PARTICIPANT DIAL IN (TOLL-FREE): 1-844-836-8741

参与者拨打（免费）：1-844-836-8741

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

参与者国际拨入：1-412-317-5442

All callers should ask for the Aethlon Medical, Inc. conference call.

所有来电者都应该要求参加Aethlon Medical, Inc.的电话会议。

A replay of the call will be available approximately one hour after the end of the call through

电话会议结束后大约一小时，将提供电话会议的重播。

July 26, 2025

2025年7月26日

. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or

回放可以通过Aethlon Medical的网站访问，或者拨打1-877-344-7529（国内）或1-412-317-0088（国际）。

Canada

加拿大

toll-free at 1-855-669-9658. The replay conference ID number is 4903201.

免费拨打1-855-669-9658。重播会议ID号码是4903201。

About Aethlon and the Hemopurifier®

关于Aethlon和Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology.

Aethlon Medical是一家医疗治疗公司，专注于开发Hemopurifier，一种临床阶段的免疫治疗设备，旨在对抗癌症和威胁生命的病毒感染，并用于器官移植。在人体研究中，Hemopurifier已显示出去除威胁生命的病毒的能力，而在临床前研究中，Hemopurifier利用其专有的基于凝集素的技术，已显示出从生物液体中去除有害外泌体的能力。

This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.

该行动在癌症方面有潜在的应用价值，其中外泌体可能促进免疫抑制和转移，并在危及生命的传染病方面也有应用。Hemopurifier 是美国食品和药物管理局 (FDA) 指定的突破性设备，用于治疗对标准治疗无反应或无法耐受的晚期或转移性癌症患者，以及外泌体已被证明参与疾病发展或严重程度的癌症类型。

The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies..

Hemopurifier还获得了FDA突破性设备认定，并且有一个与治疗未被现有疗法解决的危及生命的病毒相关的开放性研究设备豁免（IDE）申请。

Additional information can be found at

更多信息请访问

www.AethlonMedical.com

www.AethlonMedical.com

.

。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as 'may,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'plan,' 'project,' 'will,' 'projections,' 'estimate,' 'potentially' or similar expressions constitute forward-looking statements.

本新闻稿包含根据1933年《证券法》第27A条和1934年《证券交易法》第21E条所定义的前瞻性陈述，这些陈述涉及风险和不确定性。包含“可能”、“相信”、“预期”、“预计”、“打算”、“计划”、“项目”、“将”、“预测”、“估计”、“潜在”等词语或类似表达的陈述构成前瞻性陈述。

Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect.

这些前瞻性陈述受重大风险和不确定性的影响，实际结果可能与前瞻性陈述中预期的结果有实质性差异。这些前瞻性陈述基于Aethlon的当前预期，并包含可能永远不会实现或可能被证明为不正确的假设。

Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to obtain approval from the Ethics Committee of its third location in .

可能导致此类差异的因素包括但不限于：公司能否以对公司有利的条件或根本无法获得额外资本；公司能否成功完成Hemopurifier的开发；公司能否成功证明Hemopurifier在癌症、传染病及移植环境中的效用和安全性；公司能否实现并获得潜在里程碑带来的预期效益；公司能否获得其第三个地点的伦理委员会的批准。

Australia

澳大利亚

, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trials in

，包括公司预期的时间表；公司将其肿瘤临床试验中招募更多患者的能力在

Australia

澳大利亚

and

和

India

印度

, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks.

，包括公司预期的时间表；公司管理并成功完成其临床试验的能力；公司能否成功生产足够数量的Hemopurifier用于其临床试验；监管要求的意外变化；公司与UCSF长期新冠诊所的合作研究；公司进一步研究Hemopurifier在其他EV相关疾病中的潜在应用的能力，以及其他潜在风险。

The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended .

上述风险和不确定性列表是示例性的，但并不详尽。可能导致实际结果与前瞻性陈述中预期的结果存在重大差异的其他因素，可以在公司截至年度的Form 10-K年报中的“风险因素”标题下找到。

March 31, 2025

2025年3月31日

, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances..

，并在公司向证券交易委员会提交的其他文件中，包括其季度报告表格10-Q。本新闻稿中包含的所有前瞻性陈述仅在其作出之日有效。除非法律要求，公司不打算也不承担任何更新此信息以反映未来事件或情况的责任。

Company Contact:

公司联系人：

Jim Frakes

吉姆·弗雷克斯

Chief Executive Officer and Chief Financial Officer

首席执行官和首席财务官

Aethlon Medical, Inc.

Aethlon 医疗公司

Jfrakes@aethlonmedical.com

Jfrakes@aethlonmedical.com

Investor Contact:

投资者联系方式：

Susan Noonan

苏珊·努南

S.A. Noonan Communications, LLC

S.A. Noonan 通信有限责任公司

susan@sanoonan.com

苏珊@萨努南点康姆

AETHLON MEDICAL, INC. AND SUBSIDIARY

AETHLON 医疗公司及其子公司

Condensed Consolidated Balance Sheets

合并简明资产负债表

Unaudited

未审计的

ASSETS

资产

March 31, 2025

2025年3月31日

March 31, 2024

2024年3月31日

CURRENT ASSETS

流动资产

Cash and cash equivalents

现金及现金等价物

$                       5,501,261

￥ 5,501,261

$                                 5,441,978

￥ 5,441,978

Deferred offering costs

递延发行成本

-

-

277,827

277,827

Prepaid expenses and other current assets

预付费用和其他流动资产

448,539

448,539

505,983

505,983

TOTAL CURRENT ASSETS

总流动资产

5,949,800

5,949,800

6,225,788

6,225,788

Property and equipment, net

物业和设备，净值

676,220

676,220

1,015,229

1,015,229

Operating lease right-of-use asset

经营租赁使用权资产

601,846

601,846

883,054

883,054

Patents, net

专利，净值

550

550

1,100

1,100

Restricted cash

受限现金

97,813

97,813

87,506

87,506

Deposits

存款

33,305

33,305

33,305

33,305

TOTAL ASSETS

总资产

$                   7,359,534

￥ 7,359,534

$                           8,245,982

￥ 8,245,982

LIABILITIES AND STOCKHOLDERS' EQUITY

负债和股东权益

CURRENT LIABILITIES

流动负债

Accounts payable

应付账款

$                          534,524

￥ 534,524

$                                    777,862

$ 777,862

Due to related parties

由于关联方

579,565

579,565

546,434

546,434

Operating lease liability, current portion

经营租赁负债，流动部分

313,033

313,033

290,565

290,565

Accrued professional fees

应计专业费用

472,164

472,164

215,038

215,038

TOTAL CURRENT LIABILITIES

总流动负债

1,899,286

1,899,286

1,829,899

1,829,899

Operating lease liability, less current portion

经营租赁负债，减去当前部分

336,718

336,718

649,751

六十四万九千七百五十一

TOTAL LIABILITIES

总负债

2,236,004

2,236,004

2,479,650

2,479,650

STOCKHOLDERS' EQUITY

股东权益

Common stock, $0.001 par value; 60,000,000 shares authorized as of March

普通股，面值0.001美元；截至3月，已授权发行60,000,000股

31, 2025 and 2024; 2,585,239 and  328,716 shares issued and 2,010,739 and

2025年和2024年12月31日；已发行2,585,239股和328,716股，流通股为2,010,739股和

328,716 outstanding as of March 31, 2025 and March 31, 2024, respectively

截至2025年3月31日和2024年3月31日，分别为328,716股未偿还

2,586

2,586

329

329

Additional paid-in capital

附加实收资本

173,092,894

173,092,894

160,339,671

160,339,671

Accumulated other comprehensive loss

累计其他综合损失

(17,133)

(17,133)

(6,940)

（6,940）

Accumulated deficit

累积亏损

(167,954,817)

(167,954,817)

(154,566,728)

(154,566,728)

TOTAL STOCKHOLDERS' EQUITY

股东权益总计

5,123,530

5,123,530

5,766,332

5,766,332

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

总负债和股东权益

$                   7,359,534

￥ 7,359,534

$                           8,245,982

￥ 8,245,982

AETHLON MEDICAL, INC. AND SUBSIDIARY

AETHLON 医疗公司及其子公司

Consolidated Statements of Operations and Comprehensive Loss

合并经营和综合亏损表

For the fiscal years ended March 31, 2025 and 2024

截至2025年3月31日和2024年3月31日的财政年度

Unaudited

未审计的

Fiscal Year

财政年度

Fiscal Year

财政年度

Ended 3/31/25

截至25年3月31日结束

Ended 3/31/24

截至2024年3月31日

OPERATING EXPENSES

营业费用

Professional fees

专业费用

$       2,224,092

￥ 2,224,092

$       3,526,926

$ 3,526,926

Payroll and related expenses

工资和相关费用

3,874,092

3,874,092

5,206,451

5,206,451

General and administrative

一般管理和行政

3,243,181

3,243,181

3,903,191

3,903,191

Total operating expenses

总运营费用

9,341,365

9,341,365

12,636,568

12,636,568

OPERATING LOSS

营业亏损

(9,341,365)

（9,341,365）

(12,636,568)

(12,636,568)

OTHER EXPENSE (INCOME), NET

其他费用（收入），净值

Interest income

利息收入

(298,122)

(298,122)

(447,356)

(447,356)

Other income

其他收入

(324,450)

(324,450)

-

-

Interest expense

利息支出

10,109

10,109

-

-

Other expense

其他费用

4,659,188

4,659,188

18,962

18,962

Total other expense (income)

总收入（支出）

4,046,725

4,046,725

(428,394)

(428,394)

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

归属于普通股股东的净亏损

(13,388,090)

（13,388,090）

(12,208,174)

(12,208,174)

Basic and diluted net loss per share attributable to common stockholders

归属于普通股股东的基本和稀释每股净亏损

$              (8.58)

$              (8.58)

$            (38.87)

$            (38.87)

Weighted average number of common shares outstanding - basic and diluted

加权平均普通股流通股数量 - 基本和稀释

1,560,839

1,560,839

314,097

314,097

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

归属于普通股股东的净亏损

(13,388,090)

（13,388,090）

(12,208,174)

(12,208,174)

OTHER COMPREHENSIVE INCOME/(LOSS)

其他综合收益/（损失）

(10,193)

(10,193)

(799)

(799)

COMPREHENSIVE LOSS

综合亏损

$   (13,398,283)

$   (13,398,283)

$   (12,208,973)

$   (12,208,973)

SOURCE Aethlon Medical, Inc.

来源：Aethlon Medical, Inc.

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用